| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 |
Form 4: Savitz Ryan, EVP, CFO & CBO
Received 100,713 shares by exercise or conversion ($1.95M) · Sold 100,713 shares ($9.12M) · Received 2,561 shares by exercise or conversion ($56.1K) · 5 more |
| 09 Nov 2026 | 144 |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneurop... |
| 30 Oct 2026 | SCHEDULE 13G |
| 18 Sep 2026 |
Form 4: Carr Edward, CHIEF ACCOUNTING OFFICER
Received 20,000 shares by exercise or conversion ($358K) · Sold 20,000 shares ($2.03M) |
| 18 Sep 2026 | S-3ASR |
| 17 Sep 2026 | 144 |
| 03 Sep 2026 |
Form 4: Randhawa Simrat, EVP, Head of R&D
Received 23,124 shares by exercise or conversion ($477K) · Sold 23,124 shares ($2.46M) |
| 01 Sep 2026 | 144 |
| 19 Aug 2026 |
Form 4: Read Simon, Director
Received 2,778 shares by exercise or conversion ($51K) · Sold 2,778 shares ($327K) |
| 14 Aug 2026 |
Form 4: Veness Adam M, SVP, General Counsel and Sec.
Received 15,000 shares by exercise or conversion ($273K) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | SCHEDULE 13G |
| 11 Aug 2026 |
Form 4: McGeorge Anne, Director
Received 7,750 shares by exercise or conversion ($97K) · Sold 7,750 shares ($845K) |
| 11 Aug 2026 |
Form 4: Read Simon, Director
Received 2,777 shares by exercise or conversion ($51K) · Sold 2,777 shares ($304K) |
| 11 Aug 2026 |
Form 4: Veness Adam M, SVP, General Counsel and Sec.
Received 3,833 shares by exercise or conversion ($68.5K) · Sold 3,833 shares ($424K) · Received 16,167 shares by exercise or conversion ($289K) · 1 more |
| 10 Aug 2026 | 144 |
| 10 Aug 2026 | 144 |
Loading...